Biotech Investment Analyst - Specialist

Embedded Shishya; Deutschland; Remote; EUR 142.000 - 237.000; Vollzeit

Zusammenfassung

Mercor is seeking a Biotech Investment Analyst to assess drug assets and company value in a fast-paced, AI-assisted setup. This contract role focuses on analyzing development programs, clinical data, and market position to inform an investment thesis during a 1–2 week pilot with 10–20 hours per week.

The analyst will work independently and asynchronously, evaluating about 5–10 companies in the pilot and bringing 5+ years of US biotech/healthcare investment experience. Remote work is supported.

Qualifikationen

• US-based biotech/healthcare investment analyst with specialist-fund background.
• Familiarity with biotech/pharma development programs.
• Able to assess a drug asset and the company behind it end-to-end.
• 5+ years evaluating biotech/pharma companies or assets.

Aufgaben

• Create and critique rubrics that analyze commercial drugs and drug-development programs.
• Provide overall company and asset assessment, including mechanism, clinical data, competitive position, and value drivers.
• Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions.
• Apply your assessment across the pilot's set of companies, approximately 5–10.
• Work independently and asynchronously to meet deadlines and improve AI model performance.

Kenntnisse

Biotech investment

Biotech/pharma knowledge

Asset evaluation

End-to-end assessment

5+ years experience

Jobbeschreibung

About the job

Mercor connects elite creative and technical talent with leading AI research labs. Headquartered in San Francisco, our investors include Benchmark, General Catalyst, Peter Thiel, Adam D'Angelo, Larry Summers, and Jack Dorsey.

Position: Biotech Investment Analyst — Drug Asset & Company Assessment

Type:Contract

Compensation:$120–$200/hour

Location:Remote

Duration:1–2 week pilot

Commitment:10–20 hours

Role Responsibilities

• Create and critique rubrics that analyze commercial drugs and drug-development programs.
• Provide overall company and asset assessment, including mechanism, clinical data, competitive position, and value drivers.
• Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions.
• Apply your assessment across the pilot's set of companies, approximately 5–10.
• Work independently and asynchronously to meet deadlines and improve AI model performance.

Qualifications

Must-Have

• US-based biotech/healthcare investment analyst with a specialist-fund background.
• Familiarity with biotech/pharma development programs.
• Able to assess a drug asset and the company behind it end-to-end.
• 5+ years evaluating biotech/pharma companies or assets.

Compensation & Legal

• Hourly contractor